D
David Jarjoura
Researcher at Ohio State University
Publications - 106
Citations - 6791
David Jarjoura is an academic researcher from Ohio State University. The author has contributed to research in topics: Chronic lymphocytic leukemia & Antigen. The author has an hindex of 42, co-authored 105 publications receiving 6257 citations. Previous affiliations of David Jarjoura include University of Illinois at Chicago & International Breast Cancer Research Foundation.
Papers
More filters
Journal ArticleDOI
Detection of microRNA Expression in Human Peripheral Blood Microvesicles
Melissa Piper Hunter,Noura Ismail,Noura Ismail,Xiaoli Zhang,Baltazar D. Aguda,Eun Joo Lee,Lianbo Yu,Tao Xiao,Jeffrey Schafer,Mei-Ling Ting Lee,Thomas D. Schmittgen,S. Patrick Nana-Sinkam,David Jarjoura,Clay B. Marsh,Clay B. Marsh +14 more
TL;DR: This study is the first to identify and define miRNA expression in circulating plasma microvesicles of normal subjects, and provides a basis for future studies to determine the predictive role of peripheral blood miRNA signatures in human disease.
Journal ArticleDOI
Sleep disordered breathing and post-discharge mortality in patients with acute heart failure
Rami Khayat,David Jarjoura,Kyle Porter,Angela Sow,Jacob Wannemacher,Robert Dohar,Adam Pleister,William T. Abraham +7 more
TL;DR: This is the largest study to date to evaluate the effect of SDB on post-discharge mortality in patients with AHF and it shows that newly diagnosed CSA and OSA during AHF hospitalization are independently associated with post- disordered breathing mortality.
Journal ArticleDOI
Workplace based mindfulness practice and inflammation: a randomized trial.
TL;DR: It is found that MBI-ld significantly enhanced mindfulness by 2-months and it was maintained for up to a year when compared to the education control, and it seems most promising for non-obese subjects.
Journal ArticleDOI
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
Mitch A. Phelps,Thomas S. Lin,Amy J. Johnson,Eunju Hurh,Darlene M. Rozewski,Katherine L. Farley,Di Wu,Kristie A. Blum,Beth Fischer,Sarah M. Mitchell,Mollie E. Moran,Michelle Brooker-McEldowney,Nyla A. Heerema,David Jarjoura,Larry J. Schaaf,John C. Byrd,Michael R. Grever,James T. Dalton +17 more
TL;DR: In this paper, the authors reported full pharmacokinetic (PK) data, correlations of PK with clinical outcomes, and final response and progression-free survival (PFS) for patients with chronic lymphocytic leukemia (CLL).
Journal ArticleDOI
Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity.
Ergun Kocak,Kenneth D. Lute,Xing Chang,Kenneth F. May,Katie R. Exten,Huiming Zhang,Shahab F. Abdessalam,Amy Lehman,David Jarjoura,Pan Zheng,Yang Liu,Yang Liu +11 more
TL;DR: Combining anti-CTLA-4 and anti-4-1BB antibodies led to CD8 T-cell-mediated rejection of large established MC38 tumors and long-lasting immunity to the same tumor cells, although the same regimen was not effective for B16 melanoma.